Aspex Management (HK)’s New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a NFH.WS Stock Holding History

Aspex Management (HK)’s Portfolio NFH.WS Stock Details NFH.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-162,500	Closed	-$472K	–	33
2021 Q4	$472K	Hold	162,500	–	–	0.01%	26
2021 Q3	$452K	Hold	162,500	–	–	0.02%	27
2021 Q2	$427K	Hold	162,500	–	–	0.01%	24
2021 Q1	$380K	Hold	162,500	–	–	0.02%	21
2020 Q4	$354K	Hold	162,500	–	–	0.01%	23
2020 Q3	$286K	Hold	162,500	–	–	0.02%	18
2020 Q2	$221K	Hold	162,500	–	–	0.03%	13
2020 Q1	$154K	Hold	162,500	–	–	0.02%	16
2019 Q4	$249K	Buy	+162,500	New	+$229K	0.05%	12

Aspex Management (HK)'s NFH.WS Position: Q1 2022 in Review

Aspex Management (HK) sold out of New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a (NFH.WS) in Q1 2022, closing a stake of 162,500 shares — an estimated $472K sold.

Aspex Management (HK) first reported a position in NFH.WS in Q4 2019 and held it in 9 quarters. The position peaked at $472K in Q4 2021. 0 funds tracked by Wall St. Rank hold NFH.WS as of Q1 2022.

Aspex Management (HK) reported no remaining New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a position as of Q1 2022 after selling out during the quarter.
Aspex Management (HK) sold 162,500 New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a shares in Q1 2022, an estimated $472K.
Aspex Management (HK) first reported a position in New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a in Q4 2019 and held it in 9 quarters.
Aspex Management (HK)'s New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a position peaked at $472K in Q4 2021.
0 funds tracked by Wall St. Rank held New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a as of Q1 2022.

Based on Aspex Management (HK)'s 13F filing for Q1 2022, filed 9 May 2022.